Weigao Pharmaceutical Co., Ltd. and Taiwan Baoling Fujin Biotechnology Co., Ltd. to develop new kidney drug nephoxil in mainland China

Recently, Shandong Weigao Pharmaceutical Co., Ltd and Taiwan Baoling Fujin Biotechnology Co., Ltd signed a letter of intent for cooperation in Taipei city to form a joint venture The two sides will take the joint venture as the main body, give full play to their respective resource advantages, carry out the import, sales and production of naphosil ® in the mainland, and will continue to develop niche products in the field of nephrology in the future Shandong Weigao Pharmaceutical Co., Ltd., a subsidiary of Weigao group, was founded in 2003 and mainly undertakes the development of pharmaceutical industry of Weigao group In recent years, the communication and cooperation between Weigao group and Taiwan in the fields of medical treatment, biotechnology, medical devices and so on have been deepening day by day, and direct business cooperation has been established with a number of customers such as Taiwan Ruiyi medical technology company, Taipei Guotai hospital and so on On January 17, Japanese partner JT / torii was re authorized to obtain the new drug marketing license of Japan's Ministry of health and health for the new kidney drug "nephoxil" ("nephoxil") developed by Baoling Fujin Although the review meeting of Taiwan's Ministry of health and welfare held on February 19 was not approved for the time being, and the share price of 400 yuan of Wang's original new shares fell back to 390 yuan, the market is still full of expectations for the first small chemical molecule new drug certificate in Taiwan in 12 years after the application of the supplement On February 19, Taiwan's biotechnology industry attracted attention Will the Ministry of health and welfare pass the first chemical new drug developed by Taiwan and obtained the Japanese drug certificate? It is of great significance to the new kidney drug "nephoxil ® naphosphate ®", which has been independently developed by Baoling Fujin for more than ten years The answer made the stock market go down, and "nephoxil" has not been approved yet It is reported that the Ministry of health and welfare is mainly concerned with the safety and difference of dosage forms and doses used by Chinese people However, the industry is generally optimistic that there is no risk to obtain the drug certificate of the United States and Taiwan after the application for the supplement In 2001, Baoling Fujin came into contact with the kidney disease drug at the meeting, and began a long period of new drug research and development In 1976, Baoling Fujin (1760), founded by nine students from the Department of north medicine and pharmacy, transformed from pure manufacturing and agency business to specialized skin medicine and self created medical and beauty brands, including Neo living, the one Vivhuan, Baoling smart source of health care and biohair cells of hair care, etc have invested in the development of medical grade effective ingredients and dosage forms with drug development specifications, and actively created brand niche and difference.